Na+,K+-ATPase actively extrudes three cytoplasmic Na+ ions in exchange for two extracellular K+ ions for each ATP hydrolyzed. The atomic structure with bound Na+ identifies three Na+ sites, named I, II, and III. It has been proposed that site III is the first to be occupied and site II last, when Na+ binds from the cytoplasmic side. It is usually assumed that the occupation of all three Na+ sites is obligatory for the activation of phosphoryl transfer from ATP. To obtain more insight into the individual roles of the ion-binding sites, we have analyzed a series of seven mutants with substitution of the critical ion-binding residue Ser777, which is a shared ligand between Na+ sites I and III. Surprisingly, mutants with large and bulky substituents expected to prevent or profoundly disturb Na+ access to sites I and III retain the ability to form a phosphoenzyme from ATP, even with increased apparent Na+ affinity. This indicates that Na+ binding solely at site II is sufficient to promote phosphorylation. These mutations appear to lock the membrane sector into an E1-like configuration, allowing Na+ but not K+ to bind at site II, while the cytoplasmic sector undergoes conformational changes uncoupled from the membrane sector.
Serious neurological disorders are caused by mutation of Na+,K+-ATPase α1–α3 isoforms. Several disease mutations reduce the affinity for Na+, which in vivo results in an increase in the intracellular Na+ concentration with a secondary rise in intracellular Ca2+. Current treatments are ineffective, as they do not address Na+,K+-ATPase function. Hence, a platform for the development of a rational therapeutic approach that restores Na+ affinity is needed. Using the COS-1 cell expression system, one of the most conspicuous reductions in Na+ affinity of Na+,K+-ATPase has been reported for the neurological disease mutation α3-D923N of the α3 isoform. We describe here second-site mutations (“rescue mutations”) that fully restore Na+ affinity of α3-D923N and the corresponding rat α1-D928N and reveal the underlying molecular mechanism. Paradoxically, this insight evolved from investigation of a rapid-onset ataxia Na+,K+-ATPase mutant, α3-G316S, that exhibits an increased affinity for Na+. When applied as second-site mutations, α3-G316S and the corresponding rat α1-G321S are super-efficient rescuers of the reduced Na+ affinity of α3-D923N and rat α1-D928N. Replacement of the glycine with serine leads to a clash between transmembrane helices in the K+-bound E2 state of Na+,K+-ATPase but not in the Na+-bound E1 state. A similarly strong rescuing power is observed for second-site mutations breaking a salt bridge present only in the E2 state. The rescue is due to a structural change resembling the rearrangement of the ion binding sites occurring during the normal Na+,K+-ATPase transport cycle as part of the E2-to-E1 conformational transition.